John Overdeck’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-272,134
| Closed | -$10.3M | – | 4811 |
|
|
2021
Q1 | $10.3M | Sell |
272,134
-287,295
| -51% | -$7.16M | 0.03% | 700 |
|
|
2020
Q4 | $9.52M | Buy |
559,429
+106,104
| +23% | +$1.33M | 0.03% | 611 |
|
|
2020
Q3 | $2.13M | Buy |
453,325
+4,221
| +0.9% | +$21.4K | 0.01% | 1260 |
|
|
2020
Q2 | $2.74M | Buy |
449,104
+60,726
| +16% | +$250K | 0.01% | 945 |
|
|
2020
Q1 | $882K | Sell |
388,378
-85,023
| -18% | -$361K | 0.01% | 1505 |
|
|
2019
Q4 | $2.17M | Buy |
473,401
+294,034
| +164% | +$1.16M | 0.01% | 1519 |
|
|
2019
Q3 | $695K | Sell |
179,367
-61,677
| -26% | -$338K | ﹤0.01% | 2288 |
|
|
2019
Q2 | $1.45M | Buy |
241,044
+107,633
| +81% | +$1.03M | ﹤0.01% | 1654 |
|
|
2019
Q1 | $1.79M | Sell |
133,411
-118,774
| -47% | -$1.35M | 0.01% | 1494 |
|
|
2018
Q4 | $2.35M | Sell |
252,185
-34,439
| -12% | -$410K | 0.01% | 1171 |
|
|
2018
Q3 | $3.99M | Buy |
286,624
+154,735
| +117% | +$2.3M | 0.01% | 1054 |
|
|
2018
Q2 | $2.08M | Buy |
131,889
+8,294
| +7% | +$145K | 0.01% | 1579 |
|
|
2018
Q1 | $2.12M | Sell |
123,595
-17,673
| -13% | -$345K | 0.01% | 1487 |
|
|
2017
Q4 | $3.1M | Buy |
+141,268
| New | +$4.54M | 0.01% | 1186 |
|
|
2017
Q2 | – | Sell |
-38,968
| Closed | -$1.41M | – | 3408 |
|
|
2017
Q1 | $1.41M | Buy |
+38,968
| New | +$1.72M | ﹤0.01% | 1686 |
|
|
2016
Q4 | – | Sell |
-7,386
| Closed | -$388K | – | 3643 |
|
|
2016
Q3 | $388K | Sell |
7,386
-299
| -4% | -$14.3K | ﹤0.01% | 2588 |
|
|
2016
Q2 | $318K | Sell |
7,685
-95,484
| -93% | -$4.15M | ﹤0.01% | 2522 |
|
|
2016
Q1 | $4.19M | Buy |
+103,169
| New | +$3.55M | 0.02% | 792 |
|
|
2015
Q2 | – | Sell |
-48,448
| Closed | -$1.11M | – | 3207 |
|
|
2015
Q1 | $1.11M | Buy |
+48,448
| New | +$1.22M | 0.01% | 1515 |
|
John Overdeck's FPRX Position: Q2 2021 in Review
John Overdeck sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 272,134 shares — an estimated $10.3M sold.
John Overdeck first reported a position in FPRX in Q1 2015 and held it in 19 quarters. The position peaked at $10.3M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- John Overdeck reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- John Overdeck sold 272,134 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $10.3M.
- John Overdeck first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 19 quarters.
- John Overdeck's Five Prime Therapeutics, Inc. position peaked at $10.3M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Two Sigma Investments's 13F filing for Q2 2021, filed 16 Aug 2021.